TAAR1 and schizophrenia: In a four-week phase 2 trial in patients with acute exacerbation of schizophrenia, the TAAR1 agonist, ulotaront, significantly improved PANSS total scores with respect to placebo control, with a generally favourable side effect profile (including a lack of metabolic effects) [32].